Pharmacokinetic evaluation of levocetirizine

Bibliography

• Bousquet J, Reid J, van Weel C, Allergic rhinitis management pocket reference 2008. Allergy 2008;63:990-6
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Bindslev-Jensen C, Canonica W, EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006;61:321-31
   PubMed Web of Science ®Google Scholar
• Wallace DV, Dykewicz MS, Bernstein DI, The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122:S1-84
   PubMed Web of Science ®Google Scholar
• Powell RJ, Du Toit GL, Siddique N, BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007;37:631-50
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002;346:175-9
   PubMed Web of Science ®Google Scholar
• Gaig P, Olona M, Munoz LD, Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol 2004;14:214-20
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Balke M, Worm M, Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol 2010;35:869-73
   PubMed Web of Science ®Google Scholar
• Ferrer M. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergologica 2005. J Invest Allergol Clin Immunol 2009;19:21-6
   PubMed Web of Science ®Google Scholar
• Chen C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem 2008;15:2173-91
   PubMed Web of Science ®Google Scholar
• Hair PI, Scott LJ. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs 2006;66:973-96
   PubMed Web of Science ®Google Scholar
• Shimazawa R, Nagai N, Toyoshima S, Okuda H. Present state of new chiral drug development and review in Japan. J Health Sci 2008;54:23-9
   Web of Science ®Google Scholar
• Tillement JP, Testa B, Bree F. Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. Biochem Pharmacol 2003;66:1123-6
   PubMed Web of Science ®Google Scholar
• Gillard M, Van der Perren C, Moguilevsky N, Major role for the carboxylic function of cetirizine and levocetirizine in their binding characteristics to human H1-histamine-receptors. Inflamm Res 2002;51(Suppl 1):S79-80
   PubMedGoogle Scholar
• Gillard M, Van Der Perren C, Moguilevsky N, Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol Pharmacol 2002;61:391-9
   PubMed Web of Science ®Google Scholar
• Gillard M, Chatelain P. Changes in pH differently affect the binding properties of histamine H1 receptor antagonists. Eur J Pharm 2006;530:205-14
   PubMed Web of Science ®Google Scholar
• Purohit A, Melac M, Pauli G, Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003;56:388-94
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer PU, Zieglmayer R, Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol 2005;60:24-31
   PubMed Web of Science ®Google Scholar
• Gillard M, Christophe B, Wels B, H1 antagonists: receptor affinity versus selectivity. Inflamm Res 2003;52(Suppl 1):S49-50
   PubMed Web of Science ®Google Scholar
• Choi SO, Lee SH, Kong HS, Stereoselective determination of cetirizine and studies on pharmacokinetics in rat plasma. J Chromatogr B Biomed Sci Appl 2000;744:201-6
   PubMedGoogle Scholar
• Olsen L, Bondesson U, Brostrom H, Cetirizine in horses: pharmacokinetics and pharmacodynamics following repeated oral administration. Vet J 2008;177:242-9
   PubMed Web of Science ®Google Scholar
• Benedetti MS, Plisnier M, Kaise J, Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol 2001;57:571-82
   PubMed Web of Science ®Google Scholar
• Baltes E, Coupez R, Giezek H, Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 2001;15:269-77
   PubMed Web of Science ®Google Scholar
• Gillman S, Gillard M, Strolin Benedetti M. The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1 antihistamines. Allergy Asthma Proc 2009;30:366-76
   PubMed Web of Science ®Google Scholar
• Bree F, Thiault L, Gautiers G, Blood distribution of levocetirizine, a new non-sedating histamine H1-receptor antagonist, in humans. Fundam Clin Pharmacol 2002;16:471-8
   PubMed Web of Science ®Google Scholar
• Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004;18:399-411
   PubMed Web of Science ®Google Scholar
• Bartra J, Valero AL, del Cuvillo A, Interactions of the H1 antihistamines. J Investig Allergol Clin Immunol 2006;16(Suppl 1):29-36
   PubMedGoogle Scholar
• Miura M, Uno T. Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol 2010;6:69-74
   PubMed Web of Science ®Google Scholar
• Shen S, He Y, Zeng S. Stereoselective regulation of MDR1 expression in Caco-2 cells by cetirizine enantiomers. Chirality 2007;19:485-90
   PubMed Web of Science ®Google Scholar
• Strolin Benedetti M, Whomsley R, Mathy FX, Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine. Fundam Clin Pharmacol 2008;22:19-23
   PubMed Web of Science ®Google Scholar
• Wood SG, John BA, Chasseaud LF, The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann Allergy 1987;59:31-4
   PubMedGoogle Scholar
• Simons FE, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol 1995;95:685-93
   PubMed Web of Science ®Google Scholar
• Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med 2002;113(Suppl 9A):38S-46S
   PubMed Web of Science ®Google Scholar
• Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs 1999;57:31-47
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. J Allergy Clin Immunol 2005;116:355-61
   PubMed Web of Science ®Google Scholar
• Cranswick N, Turzikova J, Fuchs M, Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. Int J Clin Pharmacol Ther 2005;43:172-7
   PubMed Web of Science ®Google Scholar
• Simons FE. Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective. Pediatr Allergy Immunol 2005;16:97-103
   PubMed Web of Science ®Google Scholar
• Segall N, Gawchik S, Georges G, Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. Ann Allergy Asthma Immunol 2010;104:259-67
   PubMed Web of Science ®Google Scholar
• Hampel F, Ratner P, Haeusler JM. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy Asthma Proc 2010;31:290-5
   PubMed Web of Science ®Google Scholar
• Simons FE. Safety of levocetirizine treatment in young atopic children: an 18-month study. Pediatr Allergy Immunol 2007;18:535-42
   PubMed Web of Science ®Google Scholar
• UCB-Pharma. Xyzal 5 mg fil-coated tablets. Available from: http://www.medicines.org.uk/EMC/medicine/19877/SPC/Xyzal+5+mg+film-coated+tablets%2c+Xyzal+0.5+mg+ml+oral+solution/#MACHINEOPS 2011
   Google Scholar
• Verster JC, de Weert AM, Bijtjes SI, Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2003;169:84-90
   PubMed Web of Science ®Google Scholar
• Hulhoven R, Rosillon D, Letiexhe M, Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol 2007;63:1011-17
   PubMed Web of Science ®Google Scholar
• Leynadier F, Mees K, Arendt C, Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol Belg 2001;55:305-12
   PubMedGoogle Scholar
• Potter PC. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy 2003;58:893-9
   PubMed Web of Science ®Google Scholar
• Bachert C, Bousquet J, Canonica GW, Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838-44
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Van Hammee G, Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med 2006;100:1706-15
   PubMed Web of Science ®Google Scholar
• Day JH, Briscoe MP, Rafeiro E, Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract 2004;58:109-18
   PubMed Web of Science ®Google Scholar
• Stubner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Curr Med Res Opin 2004;20:891-902
   PubMed Web of Science ®Google Scholar
• Grant JA, Riethuisen JM, Moulaert B, A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002;88:190-7
   PubMed Web of Science ®Google Scholar
• Popov TA, Dumitrascu D, Bachvarova A, A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflamm Res 2006;55:241-4
   PubMed Web of Science ®Google Scholar
• Frossard N, Strolin-Benedetti M, Purohit A, Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol 2008;65:172-9
   PubMed Web of Science ®Google Scholar
• Kapp A, Wedi B. Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine. J Drugs Dermatol 2004;3:632-9
   PubMedGoogle Scholar
• Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 2006;45:469-74
   PubMed Web of Science ®Google Scholar
• Nettis E, Colanardi MC, Barra L, Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2006;154:533-8
   PubMed Web of Science ®Google Scholar
• Potter PC, Kapp A, Maurer M, Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy 2009;64:596-604
   PubMed Web of Science ®Google Scholar
• Anuradha P, Maiti R, Jyothirmai J, Loratadine versus levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. Indian J Pharmacol 2010;42:12-16
   PubMed Web of Science ®Google Scholar
• Staevska M, Popov TA, Kralimarkova T, The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010;125:676-82
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427-43
   PubMed Web of Science ®Google Scholar
• Boev R, Song D, Bedenbaugh A, Improving SAR symptoms with levocetirizine: evaluating active and placebo effects in pollen challenge vs. natural exposure studies. Curr Med Res Opin 2011;27:107-14
   PubMed Web of Science ®Google Scholar
• Singh-Franco D, Ghin HL, Robles GI, Levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children. Clin Ther 2009;31:1664-87
   PubMed Web of Science ®Google Scholar
• Tillement JP. A low distribution volume as a determinant of efficacy and safety for histamine (H1) antagonists. Allergy 1995;50:12-16
   PubMed Web of Science ®Google Scholar
• Walsh GM, Annunziato L, Frossard N, New insights into the second generation antihistamines. Drugs 2001;61:207-36
   PubMed Web of Science ®Google Scholar
• De Vos C, Mitchev K, Pinelli ME, Non-interventional study comparing treatment satisfaction in patients treated with antihistamines. Clin Drug Invest 2008;28:221-30
   PubMed Web of Science ®Google Scholar
• Ferrer M, Morais-Almeida M, Guizova M, Evaluation of treatment satisfaction in children with allergic disease treated with an antihistamine: an international, non-interventional, retrospective study. Clin Drug Investig 2010;30:15-34
   PubMed Web of Science ®Google Scholar
• Maurer M, Ortonne JP, Zuberbier T. Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor-patient relation. Allergy 2009;64:581-8
   PubMed Web of Science ®Google Scholar
• Ferrer M, Jauregui I, Bartra J, Chronic urticaria: do urticaria nonexperts implement treatment guidelines? A survey of adherence to published guidelines by nonexperts. Br J Dermatol 2009;160:823-7
   PubMed Web of Science ®Google Scholar
• Gillard M, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res 2005;54:367-9
   PubMed Web of Science ®Google Scholar
• del Cuvillo A, Mullol J, Bartra J, Comparative pharmacology of the H1 antihistamines. J Invest Allergol Clin Immunol 2006;16(Suppl 1):3-12
   PubMedGoogle Scholar
• Passalacqua G, Canonica GW. A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis. Clin Ther 2005;27:979-92
   PubMed Web of Science ®Google Scholar
• Deruaz C, Leimgruber A, Berney M, Levocetirizine better protects than desloratadine in a nasal provocation with allergen. J Allergy Clin Immunol 2004;113:669-76
   PubMed Web of Science ®Google Scholar
• Lee DK, Gardiner M, Haggart K, Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004;34:650-3
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cirillo I, Vizzaccaro A, Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005;5:1800-8
   PubMed Web of Science ®Google Scholar
• Hong JB, Lee HC, Hu FC, A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria. J Am Acad Dermatol 2010;63:e100-2
   PubMed Web of Science ®Google Scholar
• McConathy J, Owens MJ. Stereochemistry in drug action. Prim Care Companion J Clin Psychiatry 2003;5:70-3
   PubMedGoogle Scholar